Maximize catheter patency, minimize risk*
4% sodium citrate lock solution reduced the number of hemodialysis catheters exchanged per 1,000 days by 59% vs heparin 5,000 U/mL (1.33 vs 3.24, p = 0.002).1
Fewer CRBSIs vs heparin 5,000 U/mL*
45% fewer catheter-related bloodstream infections (CRBSIs) (11 vs 20; p = 0.026) and 57% fewer CRBSIs/1,000 catheter-days (0.81 vs 1.90; p = 0.026).1
Supported by guidelines
Recommended by several international guidelines, including INS 20162, CVAA 20133, CANNT4, ASDIN 20085 and ERBP 2007.6
Fewer bleeding events vs heparin 5,000 U/mL*
67% reduction in systemic bleeding events (7 vs 21; p = 0.035) with no risk of heparin-induced thrombocytopenia.6
Equivalent anticoagulation and maintenance of catheter patency 1,7–10*
Similar antithrombotic efficacy and maintenance of catheter function vs heparin 5,000–10,000 U/mL.
Equivalent patency without heparin-related adverse events 1,7–10*
Not associated with systemic anticoagulation, bleeding risks or heparin-induced thrombocytopenia (HIT).
Associated with significantly fewer CRBSIs 1,7–10*
Significantly fewer CRBSI with 4% sodium citrate vs 5,000 U/mL heparin (0.81 vs 1.90/1,000 catheter-days, p = 0.026).
May help prevent biofilm formation 11,12*
Efficiently inhibits biofilm formation and cell growth of S. aureus and S. epidermidis.
Improve CVC dwell time 1,7–10*
Time from catheter insertion to CVC exchange was significantly improved (p = 0.04).
May be more cost-effective than heparin locks in vials 7,9*
Up to 85% reduction in the costs associated with catheter-locking vs. heparin. 8
* Current data only validated in hemodialysis catheters.